INTELLIA THERAPEUTICS, INC. Current Liabilities
INTELLIA THERAPEUTICS, INC. (NTLA) had Current Liabilities of $79.39 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Liabilities, Current $79.39M.
- 2026-03-31: Liabilities, Current $76.44M.
- 2025-12-31: Liabilities, Current $103.88M.
- 2025-09-30: Liabilities, Current $93.73M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $79.39M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $76.44M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $103.88M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $93.73M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $95.50M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $112.59M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $110.85M 10-K · filed 2026-02-26 |
| 2024-09-30 | $105.68M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $105.09M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $97.91M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $115.21M 10-K · filed 2025-02-27 |
| 2023-09-30 | $91.95M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $99.85M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $103.38M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $126.55M 10-K · filed 2024-02-22 |
| 2022-09-30 | $131.13M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $123.76M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $126.11M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $125.83M 10-K · filed 2023-02-23 |
| 2021-09-30 | $97.57M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $73.96M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $60.70M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $64.25M 10-K · filed 2022-02-24 |
| 2020-09-30 | $55.87M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $59.14M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $35.30M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $35.63M 10-K · filed 2021-02-26 |
| 2019-09-30 | $37.52M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $38.46M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $39.23M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $40.57M 10-K · filed 2020-02-27 |
| 2018-09-30 | $25.91M 10-Q · filed 2018-10-31 |
| 2018-06-30 | $25.17M 10-Q · filed 2018-08-01 |
| 2018-03-31 | $25.58M 10-Q · filed 2018-05-01 |
| 2017-12-31 | $31.36M 10-K · filed 2019-02-27 |
| 2017-09-30 | $25.79M 10-Q · filed 2017-10-31 |
| 2017-06-30 | $26.37M 10-Q · filed 2017-08-01 |
| 2017-03-31 | $24.91M 10-Q · filed 2017-05-02 |
| 2016-12-31 | $30.73M 10-K · filed 2018-03-14 |
| 2016-09-30 | $22.63M 10-Q · filed 2016-11-01 |
| 2016-06-30 | $21.62M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $10.96M 10-Q · filed 2016-06-03 |
| 2015-12-31 | $10.70M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |